Hims & Hers Health (NYSE:HIMS) Stock Price Down 7.7% Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) dropped 7.7% during mid-day trading on Friday after an insider sold shares in the company. The stock traded as low as $11.20 and last traded at $11.30. Approximately 7,689,312 shares were traded during mid-day trading, an increase of 66% from the average daily volume of 4,621,117 shares. The stock had previously closed at $12.24.Specifically, insider Soleil Boughton sold 4,080 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the transaction, the insider now directly owns 154,345 shares of the company's stock, valued at approximately $1,548,080.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of Hims & Hers Health stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40. Following the transaction, the insider now directly owns 154,345 shares of the company's stock, valued at $1,548,080.35. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Melissa Baird sold 11,750 shares of the firm's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the completion of the transaction, the chief operating officer now directly owns 538,932 shares in the company, valued at approximately $6,510,298.56. The disclosure for this sale can be found here. Insiders sold a total of 736,191 shares of company stock valued at $9,733,700 in the last 90 days. 31.63% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HIMS. Leerink Partnrs reaffirmed a "market perform" rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a "buy" rating and a $20.00 price target for the company. Seaport Res Ptn reaffirmed a "buy" rating on shares of Hims & Hers Health in a report on Friday, April 26th. TheStreet upgraded shares of Hims & Hers Health from a "d" rating to a "c" rating in a research report on Monday, March 4th. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $14.85.

Hims & Hers Health Stock Performance

The firm has a 50 day moving average of $13.97 and a 200-day moving average of $10.22. The stock has a market capitalization of $2.41 billion, a PE ratio of -103.27 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. During the same period in the prior year, the business posted ($0.05) earnings per share. Hims & Hers Health's revenue for the quarter was up 47.4% compared to the same quarter last year. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.11 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at about $48,000. Cornerstone Investment Partners LLC bought a new stake in Hims & Hers Health during the first quarter valued at about $161,000. EMC Capital Management increased its stake in shares of Hims & Hers Health by 80.0% in the third quarter. EMC Capital Management now owns 12,000 shares of the company's stock worth $79,000 after purchasing an additional 5,332 shares during the period. Belpointe Asset Management LLC bought a new stake in Hims & Hers Health in the 3rd quarter valued at $76,000. Finally, Certuity LLC acquired a new stake in Hims & Hers Health during the fourth quarter valued at approximately $109,000. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.